INmune Bio (INMB) is hosting a Webinar on November 7, 2024. The webinar, titled “Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer’s Trials,” will explore the development of EMACC and its advantages in assessing cognitive changes over time in early Alzheimer’s Disease patients. It will also cover the regulatory landscape for Alzheimer’s disease drug development and the role of the CDR-SB clinical scale. Speakers include Dr. Judith Jaeger, President of CognitionMetrics and leader of the team that developed and validated EMACC, Dr. Sarah Barnum, and CJ Barnum, VP of CNS Drug Development at INmune Bio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio announces publication of XPro1595 data in Cell Reports
- INmune Bio initiated with a Buy at Alliance Global Partners
- INmune Bio completes enrollment for Phase 2 trial in Early AD
- INmune Bio initiated with an Outperform at Raymond James
- INmune announces initial results from Phase I/II trial of INKmune with mCRPC